ASMB · XBRL financial data

Assembly Biosciences financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (ASMB's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024†Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	—	—	—	—	28,520	72,303
Research and development	106,823	68,524	69,980	48,900	55,933	64,813
General and administrative	37,058	28,780	24,134	22,909	18,007	19,608
Total operating expenses	143,881	138,942	94,114	71,809	73,940	84,421
Operating income (loss)	(64,776)	(132,688)	(94,114)	(64,646)	(45,420)	(12,118)
Income tax expense (benefit)	0	(2,531)	0	33	330	0
Net income (loss)	(62,152)	(129,855)	(93,092)	(61,228)	(40,177)	(6,122)
Earnings per share, basic‡ USD per share	—	(36.01)	(23.05)	(160.62)	(6.69)	(0.55)
Earnings per share, diluted‡ USD per share	—	(36.01)	(23.05)	(160.62)	(6.69)	(0.55)
Weighted average shares, basic‡ thousands of shares	—	3,605	4,032	381	6,005	11,211
Weighted average shares, diluted‡ thousands of shares	—	3,605	4,032	381	6,005	11,211

‡ Per-share figures and share counts are adjusted for the 1-for-12.004801920768308 stock split (February 2024); filings made before it reported them unadjusted.
† Share count changed about 16x in the period ending 2024-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal years (ASMB's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024†Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	59,444	45,627	52,418	19,841	38,344	58,450
Marketable securities	156,969	101,000	39,192	110,406	73,735	189,656
Marketable securities, non-current	0	27,972	0	—	—	—
Accounts receivable	1,230	336	944	43	0	974
Prepaid and other current assets	6,850	7,241	4,413	3,497	3,424	5,469
Total current assets	224,493	154,204	96,967	133,787	115,503	254,549
Property and equipment, net	1,600	1,139	743	385	284	221
Right-of-use asset	9,131	6,042	3,195	2,339	3,069	2,508
Goodwill	12,638	—	—	—	—	—
Total assets	283,254	191,060	101,794	136,823	119,168	257,590
Accounts payable	4,598	2,659	2,493	461	585	1,171
Accrued liabilities	11,987	6,863	7,317	5,744	6,862	7,749
Total current liabilities	24,433	16,073	16,296	39,225	47,803	48,780
Lease liability, non-current	6,725	3,325	101	1,122	2,628	2,059
Total liabilities	42,676	22,131	19,130	95,726	85,809	50,839
Accumulated deficit	(501,573)	(631,428)	(724,520)	(785,748)	(825,925)	(832,047)
Total stockholders' equity	240,578	168,929	82,664	41,097	33,359	206,751
Total liabilities and equity	283,254	191,060	101,794	136,823	119,168	257,590
Common shares outstanding (cover page)‡ thousands of shares	3,186	4,008	4,327	457	7,503	15,863

‡ Per-share figures and share counts are adjusted for the 1-for-12.004801920768308 stock split (February 2024); filings made before it reported them unadjusted.
† Share count changed about 16x in the period ending 2024-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal years (ASMB's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024†Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(62,152)	(129,855)	(93,092)	(61,228)	(40,177)	(6,122)
Stock-based compensation	21,853	5,237	6,593	5,119	3,120	4,677
Depreciation and amortization	691	466	498	450	129	129
Net cash from operating activities	(62,957)	(93,396)	(84,463)	22,743	(51,117)	(41,093)
Purchases of property and equipment	470	3,096	102	255	28	66
Net cash from investing activities	68,070	26,515	90,640	(69,138)	40,171	(113,468)
Proceeds from issuing common stock	5,452	52,806	325	4,546	2,030	1,922
Net cash from financing activities	7,599	53,064	614	13,818	29,449	174,667
Net change in cash	12,712	(13,817)	6,791	(32,577)	18,503	20,106

† Share count changed about 16x in the period ending 2024-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Assembly Biosciences	32,286	not reported	(15,488)*	20.4M	20.7 quarters	Q2 FY26 10-QJun 30, 2026
Milestone Pharmaceuticals	169,728	559	(22,714)*	124.5M	7.5 quarters	Q2 FY26 10-QJun 30, 2026
DiaMedica Therapeutics	5,129	not reported	(8,114)*	53.9M	5.4 quarters	Q2 FY26 10-QJun 30, 2026
Larimar Therapeutics	92,687	not reported	(44,030)*	103.9M	3.5 quarters	Q2 FY26 10-QJun 30, 2026
Ironwood Pharmaceuticals	79,127	113,041	58,276*	165.2M	—	Q2 FY26 10-QJun 30, 2026
Vaxart	50,929	27,185	2,778*	242.8M	—	Q2 FY26 10-QJun 30, 2026
Achieve Life Sciences	47,958	not reported	(10,777)*	102.9M	17.4 quarters	Q2 FY26 10-QJun 30, 2026
Fennec Pharmaceuticals	41,249	17,874	50*	35.1M	—	Q2 FY26 10-QJun 30, 2026
Atossa Therapeutics	26,094	not reported	(9,644)*	10.0M	2.7 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.